Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).
1 finding from 1 review
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ superficial infection · adults with open long bone fractures of the upper and lower limbs
It is very uncertain whether timing of wound closure (immediate changes adverse events ‐ superficial infection compared with delayed) (very low certainty).
1 finding from 1 review
Patients with one or more adverse events · Patients requiring surgical removal of a lower wisdom tooth or teeth, with baseline moderate to severe pain (surgery under local…
Paracetamol (single oral dose, any dose or formulation; subgroups up… showed no clear difference in patients with one or more adverse events compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · children with acute asthma
Children: higher dose/longer course showed no clear difference in all adverse events compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
Standard‐protein formula showed no clear difference in adverse events compared with low‐protein formula (low certainty).
1 finding from 1 review
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
High‐protein formula showed no clear difference in adverse events compared with standard‐protein formula (low certainty).
1 finding from 1 review
Adverse events · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Adverse events · children with CP
The review found no eligible studies for this question.
3 findings from 1 review
Adverse events · children with CP
BoNT‐A showed no clear difference in adverse events compared with placebo or sham (moderate certainty).
3 findings from 1 review
Adverse events · children with CP
BoNT‐A showed no clear difference in adverse events compared with serial casting (low certainty).
3 findings from 1 review
Adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events
PDEI may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events
PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate